Financial Performance - The company's operating revenue for Q3 2023 was ¥171,141,686.51, representing an increase of 8.24% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥49,124,978.29, showing a growth of 2.09% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥40,888,943.19, which is a decrease of 7.94% compared to the previous year[6]. - The basic earnings per share for Q3 2023 remained at ¥0.25, unchanged from the previous quarter[6]. - Total operating revenue for the first three quarters of 2023 reached ¥542,632,310.78, an increase of 6.9% compared to ¥507,644,677.94 in the same period of 2022[20]. - Net profit for the first three quarters of 2023 was ¥139,360,766.88, compared to ¥130,139,899.65 in 2022, marking an increase of 7.5%[22]. - Basic and diluted earnings per share for the first three quarters of 2023 were both ¥0.71, up from ¥0.67 in the same period of 2022[22]. - The company reported a total comprehensive income of ¥144,748,615.72 for the first three quarters of 2023, compared to ¥126,986,463.35 in 2022, an increase of 14.0%[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,977,144,207.80, an increase of 4.23% from the end of the previous year[6]. - The company's current assets totaled RMB 1,743,032,947.68, down from RMB 1,862,011,357.39 at the end of 2022, indicating a decrease of about 6.36%[15]. - The total liabilities amounted to RMB 511,803,494.42, compared to RMB 477,765,151.63 at the end of 2022, indicating an increase of about 7.10%[16]. - The total liabilities as of the end of the third quarter of 2023 were ¥918,578,758.60, down from ¥950,667,244.96 at the end of 2022, a reduction of 3.4%[17]. - Total equity attributable to shareholders reached ¥2,058,565,449.20, an increase from ¥1,905,522,314.70 in 2022, representing an increase of 8.0%[17]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥194,838,611.40, which is a decrease of 11.35% year-on-year[6]. - Cash flow from operating activities for the first three quarters of 2023 was ¥194,838,611.40, a decrease from ¥219,792,085.51 in 2022[24]. - Net cash inflow from investment activities was $65.71 million, while cash outflow totaled $339.24 million, resulting in a net cash flow of -$273.53 million[25]. - Cash inflow from financing activities reached $970.64 million, with cash outflow amounting to $1.07 billion, leading to a net cash flow of -$97.02 million[25]. - The ending balance of cash and cash equivalents was $1.09 billion, down from $1.27 billion at the beginning of the period[25]. - The company reported a significant increase in borrowing, with cash received from loans totaling $510.24 million, compared to $188.65 million in the previous period[25]. - Cash paid for debt repayment was $445 million, indicating a focus on managing liabilities[25]. - The net cash increase for the period was -$175.71 million, contrasting with a positive increase of $106.63 million in the previous period[25]. - The company's cash flow from investment activities was notably negative, reflecting ongoing investments and capital expenditures[25]. - The total cash outflow for financing activities was significantly higher than the previous period, indicating increased financial activity[25]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,701[11]. - The top shareholder, Zhejiang Shouxian Valley Investment Management Co., Ltd., holds 28.10% of the shares, totaling 56,711,239 shares[12]. - The company completed a share buyback of 3,585,000 shares, representing 1.78% of the total share capital as of September 30, 2023[14]. Research and Development - Research and development expenses for the first three quarters of 2023 totaled ¥39,846,073.99, compared to ¥37,938,562.04 in 2022, indicating an increase of 5.0%[20]. Strategic Plans - The company plans to continue its market expansion and product development strategies, although specific new products and technologies were not detailed in the report[14].

| 债券代码：113660 | 债券简称：寿 22 | 转债 | | --- | --- | --- | | 证券代码：603896 | 证券简称：寿仙谷 | 公告编号：2023-058 | 浙江寿仙谷医药股份有限公司 关于注销部分募集资金专项账户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 1、"寿仙转债"募集资金基本情况 为规范公司本次发行的募集资金管理及使用，保护中小投资者权益，根据中 国证监会《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》、上海证券交易所《上市公司自律监管指引第 1 号——规范运作》等法律、 法规的规定，2022 年 11 月 23 日，公司与招商银行股份有限公司金华分行（以 序 号 公司名称 开户银行 账号 募投项目 账户状 态 1 浙江寿仙谷医药 股份有限公司 建设银行 武义支行 33050167732700001745 / 本次销户 2 武义寿仙谷中药 饮片有限公司 工商银行 武义支行 1208060029000515117 寿仙谷健康产业 ...

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-057 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 经上海证券交易所自律监管决定书[2022]332 号文同意，公司 39,800.00 万元 关于"寿 22 转债"转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、"寿 22 转债"发行上市概况 经中国证券监督管理委员会"证监许可[2022]2165 号"文核准，公司于 2022 年 11 月 17 日公开发行 398 万张可转换公司债券，每张面值 100 元，发行总额 39,800 万元，按面值发行，期限 6 年；债券利率：第一年为 0.5%、第二年为 0.8%、 第三年为 1%、第四年为 1.5%、第五年为 2%、第六年为 2.5%。 "寿 22 转债"转股情况：自 2023 年 5 月 23 日至 2023 年 9 月 30 日， "寿 22 ...

特此公告。 浙江寿仙谷医药股份有限公司董事会 2023 年 9 月 28 日 近日，浙江寿仙谷医药股份有限公司（以下简称"公司"）全资子公司金华 寿仙谷药业有限公司的"寿仙谷牌辅酶 Q10 片"产品完成了国产保健食品备案 工作，并获得浙江省市场监督管理局发放的国产保健食品备案凭证。具体情况如 下： | 产品名称 | 寿仙谷牌辅酶 片 Q10 | | --- | --- | | 保健功能 | 有助于增强免疫力和有助于抗氧化 | | 备案号 | 食健备 G202333003036 | | 备案人 | 金华寿仙谷药业有限公司 | | 备案人地址 | 浙江省金华市武义县黄龙开发区三路 号 12 | | 备案结论 | 按照《中华人民共和国食品安全法》、《保健食品注册与备案 管理办法》等法律、规章的规定，予以备案。 | 上述产品备案成功不会对公司近期的生产经营产生重大影响，但有利于进一 步补充完善公司的产品品类，丰富公司的产品线，提升公司在保健食品领域的竞 争力，符合公司布局大健康产业的战略规划，为企业持续发展打下扩容基础。 | 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-056 | | - ...

近日，公司完成了工商变更登记手续，并取得了浙江省市场监督管理局换发 的营业执照，相关登记信息如下： 经上海证券交易所自律监管决定书[2020]180 号文同意，浙江寿仙谷医药股 份有限公司（以下简称"公司"）36,000.00 万元可转换公司债券于 2020 年 7 月 7 日起在上交所挂牌交易，债券简称"寿仙转债"，债券代码"113585"。根据《上海 证券交易所股票上市规则》等有关法律法规的规定和《浙江寿仙谷医药股份有限 公司公开发行可转换公司债券募集说明书》的约定，公司本次发行的"寿仙转债" 自 2020 年 12 月 15 日起可转换为公司 A 股普通股股票。自 2020 年 12 月 15 日 至 2022 年 12 月 31 日，寿仙转债累计因转股形成的股份数量为 9,071,690 股，公 司总股本由 197,195,916 股变更为 197,203,347 股，注册资本由 197,195,916.00 元 变更为 197,203,347.00 元。公司于 2023 年 5 月 9 日召开 2022 年年度股东大会， 审议并通过了《关于变更公司注册资本并修订<公司章程>部分条款的议案》，决 议变 ...

| 证券代码：603896 | 证券简称：寿仙谷 | 公告编号：2023-054 | | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | 浙江寿仙谷医药股份有限公司 关于竞得杭州运河恒立商业地产有限公司 100%股权 进展暨完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、交易概述 浙江寿仙谷医药股份有限公司（以下简称"寿仙谷"或"公司"）于 2023 年 7 月 17 日召开寿仙谷第四届董事会第十四次会议，以全票同意审议通过《寿 仙谷关于拟参与杭政储出【2020】79 号地块项目公司股权及债权竞拍暨签订收 购意向书的议案》，同意参与竞购杭州运河集团建设管理有限公司在杭州产权交 易所有限责任公司公开挂牌转让的杭州运河恒立商业地产有限公司（以下简称 "恒立公司"）100%股权事项，并于 2023 年 8 月 18 日被确认为本次竞购的受 让方。2023 年 8 月 21 日，公司与运河建管公司签署《股权转让协议》，股权转 让价格 1,000.00 元 ...

会议召开时间：2023 年 09 月 13 日（星期三） 下午 15:00-16:30 会议召开地点： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：视频录播结合网络互动，公司通过文字直播方式回复 投资者提问。 投资者可于 2023 年 09 月 06 日（星期三）至 09 月 12 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮 箱 sxg@sxgoo.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 | | | 债券代码：113660 债券简称：寿 22 转债 浙江寿仙谷医药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江寿仙谷医药股份有限公司（以下简称"公司"）于 2023 年 08 月 25 日发 布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半 年度经 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with a year-on-year growth of 15%[1]. - The company's operating revenue for the first half of 2023 reached ¥371,490,624.27, representing a 6.28% increase compared to ¥349,529,536.21 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥90,235,788.59, up 10.02% from ¥82,016,514.61 year-on-year[22]. - The net profit after deducting non-recurring gains and losses increased by 17.13%, amounting to ¥77,577,711.43 compared to ¥66,230,454.06 in the previous year[22]. - The total revenue for the first half of 2023 was CNY 30,561.05 million, compared to CNY 70,163.88 million for the entire year of 2022[82]. - The company achieved a revenue of 371.49 million yuan in the first half of 2023, representing a year-on-year growth of 6.28%[65]. - The net profit attributable to shareholders reached 90.24 million yuan, an increase of 10.02% compared to the previous year[65]. - The net profit after deducting non-recurring gains and losses was 77.58 million yuan, reflecting a growth of 17.13% year-on-year[65]. Market Expansion and Product Development - User data indicates a rise in active customers, reaching 1.2 million, which is a 20% increase compared to the same period last year[1]. - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 15%[1]. - New product launches are expected to contribute an additional 5% to overall revenue in the upcoming quarters[1]. - Market expansion plans include entering two new provinces, aiming for a 30% increase in market share by the end of 2024[1]. - The company plans to continue expanding its market presence and invest in new product development to drive future growth[26]. - The company launched the "Shouxiangu brand Melatonin Capsules" and completed the filing process, showcasing its innovation in product development[69]. - The company is actively pursuing international expansion by entering platforms like Alibaba International Station and Amazon, as well as participating in cross-border exhibitions[66]. Research and Development - The company is investing in R&D, with a budget increase of 25% for new technology development[1]. - The company received 3 authorized invention patents and 5 design patents, indicating a strong focus on research and development[69]. - The company has developed three new high-yield and high-efficacy varieties of Dendrobium, namely "Xianhu 1", "Xianhu 2", and "Xianhu 3", with "Xianhu 2" achieving a polysaccharide content of 58.7%, exceeding the pharmacopoeia standard by over 100%[54]. - The company has established a comprehensive industry chain from breeding, cultivation, research and development, production, to sales, and is the only enterprise mastering the wall-breaking technology in the industry[44]. - The company has developed a unique "four lows and one high" ultra-sound low-temperature airflow breaking technology for Ganoderma spores, significantly improving product safety and efficacy[59]. Financial Position and Cash Flow - The company maintains a strong cash position, with cash reserves amounting to 500 million RMB, ensuring liquidity for future investments[1]. - The net cash flow from operating activities decreased by 12.82%, totaling ¥161,197,397.61, down from ¥184,897,406.74 in the same period last year[22]. - The total assets of the company at the end of the reporting period were ¥3,026,512,983.11, reflecting a 5.96% increase from ¥2,856,189,559.66 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company increased by 5.46%, reaching ¥2,009,578,257.55 compared to ¥1,905,522,314.70 at the end of the previous year[22]. - The company's cash and cash equivalents increased to CNY 1,696,397,838.47 from CNY 1,524,712,390.54 as of December 31, 2022, reflecting a growth of approximately 11.3%[150]. - The total current liabilities rose to CNY 617,860,610.35, up from CNY 477,765,151.63, indicating an increase of about 29.4%[151]. Operational Efficiency and Cost Management - Operating costs increased by 27.10% to ¥66,695,773.39 from ¥52,475,316.24 year-on-year, primarily due to rising raw material costs and increased depreciation from convertible bond projects[77]. - The gross margin for the manufacturing sector was 84.04%, with a slight decrease of 2.43% compared to the previous year[79]. - The gross margin for Ganoderma spore powder products was 87.77% in the first half of 2023, maintaining above 87% for several years[81]. - The company has implemented a digital transformation strategy, creating a "smart farm + smart factory + smart market" system to enhance operational efficiency across its production and sales processes[61]. - The company has completed the construction of 16 major projects, including the Biological Breeding Innovation Center, enhancing its operational capabilities[71]. Environmental and Social Responsibility - The company has maintained a proactive approach to environmental management, ensuring that all waste, including hazardous waste, is disposed of by licensed entities[108]. - The company has received no administrative penalties related to environmental issues, reflecting its commitment to environmental protection[107]. - The company has actively engaged in community support and charity, contributing cash and materials to various local organizations[114]. - The company has implemented measures to reduce emissions, including saving 290,116 kg of standard coal and reducing CO2 emissions by 774,276 kg annually[112]. Corporate Governance and Compliance - The company did not propose any profit distribution or capital reserve increase for the first half of 2023, indicating a focus on reinvestment[104]. - The company has not disclosed any new employee incentive plans or stock options, suggesting stability in its current management structure[105]. - The company has committed to timely and accurate information disclosure in accordance with legal requirements[119]. - The company has ensured compliance with relevant laws and regulations regarding related party transactions and will not seek undue advantages[118]. Shareholder Information - The company issued 36 million yuan of convertible bonds, which were fully redeemed on June 6, 2023, with a total of 4,625,061 shares converted from these bonds[129]. - As of June 30, 2023, the total number of shares increased to 201,828,408, with 197,203,347 shares before the conversion[127]. - The family of Li Mingyan, including Li Zhenhao and Li Zhenyu, collectively holds 38.08% of the company's shares, indicating a strong family control over the company[135]. - The total number of shares held by the top ten unrestricted shareholders is 56,711,239, with Li Zhenhao holding 15,041,650 shares[134].

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2023-050 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江寿仙谷医药股份有限公司（以下简称"公司"）第四届董事会第十五次 会议于 2023 年 8 月 24 日在公司会议室以现场和通讯表决相结合的方式召开，会 议通知于 2023 年 8 月 14 日以电子邮件形式发出，会议应到董事 9 名，实到董事 9 名，公司监事、高级管理人员、董事会秘书及证券事务代表列席了会议。本次 会议由董事长李明焱先生主持，会议的召开符合《公司法》及《公司章程》的有 关规定。 二、董事会会议审议情况 1、审议并通过《浙江寿仙谷医药股份有限公司 2023 年半年度报告》（全文 及摘要） 第四届董事会第十五次会议决议公告 特此公告。 2023 年 8 月 25 日 表决结果：同意票 9 票，反对票 0 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 | 证券代码：603896 | 证券简称：寿仙谷 | 公告编号：2023-51 | | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | 浙江寿仙谷医药股份有限公司 第四届监事会第十次会议决议公告 1、审议并通过《浙江寿仙谷医药股份有限公司 2023 年半年度报告》（全文 及摘要） 公司监事会认为，公司 2023 年半年度报告系依据中国证监会《公开发行证 券的公司信息披露内容与格式准则第 3 号——半年度报告的内容与格式（2021 年修订）》、上海证券交易所《股票上市规则》等有关规定编制，报告真实、准确、 完整地反映了公司的财务状况和经营成果，在报告编制和审议期间未发现内幕信 息泄露的情况或其他损害公司利益的行为。 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 2、审议并通过《浙江寿仙谷医药股份有限公司 2023 年半年度募集资金存放 与实际使用情况的专项报告》 公司监事会认为，公司 202 ...